Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 44

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 44
---
 Ph.D.        |     |                                            2,154,651 |     |                             521,125 |     |                      5,569,100 |     |       521,125 |     |                                       $1,309,750 |     |                      $1,073,518 |
| Blaine Davis                |     |                                            1,250,000 |     |                                   — |     |                      1,250,000 |     |             — |     |                                         $987,500 |     |                               — |
| Metin Kurtoglu, M.D., Ph.D. |     |                                                    — |     |                                   — |     |                              — |     |             — |     |                                                — |     |                               — |
| Christopher Jewell, Ph.D.   |     |                                                    — |     |                                   — |     |                              — |     |             — |     |                                                — |     |                               — |

Old Cartesian Options and Adoption of Old Cartesian’s 2016 Stock Incentive Plan

At the Effective Time, each option to purchase shares of Old Cartesian common stock (an “Old Cartesian Option”), other than Old Cartesian Options held by Drs. Kurtoglu, Miljkovic, and Jewell, that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, was converted into an option to purchase Common Stock. At the Effective Time, each Old Cartesian Option held by Drs. Kurtoglu, Miljkovic, and Jewell (a “Continuing Officer Option”) that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, was converted into an option to purchase Series A Preferred Stock. Pursuant to the Merger Agreement, we assumed the Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan (the “Old Cartesian Plan”) and each Old Cartesian Option in accordance with the terms of the Old Cartesian Plan and the terms of the stock option agreement by which such Old Cartesian Option is evidenced (but with changes to such documents as we in good faith determined were necessary to reflect the substitution of Old Cartesian Options by us to purchase shares of Common Stock or Series A Preferred Stock, as applicable, and the other terms set forth in the Merger Agreement). All rights with respect to Old Cartesian common stock under Old Cartesian Options assumed by the Company were converted into rights with respect to Common Stock or Series A Preferred Stock, as applicable. From and after the Effective Time